Literature DB >> 33633984

A nomogram of preoperative predictors for occult metastasis in patients with PDAC during laparoscopic exploration.

Jiachen Ge1, Lei Li1, Zhaolai Ma1, Bin Jiang1, Chunhui Yuan1, Hangyan Wang1, Ying Peng1, Dianrong Xiu1.   

Abstract

BACKGROUND: Surgical resection is the only potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC). However, most of patients lose the chance of surgery due to the unresectable disease at the time of diagnosis. Despite the improvement of radiological imaging, a portion of patients intended for radical resection were proven to be unresectable at surgical exploration due to occult metastasis.
METHODS: Patients who were aimed to undergo radical pancreatectomy for PDAC from 2010 to 2019 were reviewed retrospectively. All patients included underwent diagnostic laparoscopic exploration. Patients were divided into two groups depending on whether distant metastasis were encountered during exploration. Univariate and multivariate logistic regression analyses were used to identify risk factors for occult metastasis. A nomogram to predict occult metastasis of PDAC on exploration was developed and evaluated.
RESULTS: A total of 273 patients who underwent diagnostic laparoscopic exploration were included in this study. Nineteen (7.0%) patients were found with distant metastasis during exploration. Multivariate logistic regression analysis showed that ALT>40U/L, CA19-9, CA125 and regional nodes enlargement were independent predictors for occult metastasis. Incorporating these four factors, the nomogram achieved concordance index of 0.799, with a well-fitted calibration curve.
CONCLUSIONS: Occult metastasis is not unusual during surgical exploration in patients with resectable or borderline resectable PDAC. The nomogram could achieve a personal prediction of unexpected distant metastasis on exploration. It may help to sift through patients with PDAC who would benefit from laparoscopic exploration. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Pancreatic ductal adenocarcinoma (PDAC); laparoscopic exploration; nomogram; occult metastasis; risk factors

Year:  2021        PMID: 33633984      PMCID: PMC7882304          DOI: 10.21037/gs-20-605

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  40 in total

1.  Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients.

Authors:  Zhi Ven Fong; Donna Marie L Alvino; Carlos Fernández-Del Castillo; Winta T Mehtsun; Ilaria Pergolini; Andrew L Warshaw; David C Chang; Keith D Lillemoe; Cristina R Ferrone
Journal:  Ann Surg Oncol       Date:  2017-07-17       Impact factor: 5.344

2.  Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.

Authors:  Labrinus van Manen; Jesse V Groen; Hein Putter; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg; Bert A Bonsing; J Sven D Mieog
Journal:  Biomarkers       Date:  2020-02-13       Impact factor: 2.658

3.  Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth?

Authors:  Elliot Tapper; Bobby Kalb; Diego R Martin; David Kooby; N Volkan Adsay; Juan M Sarmiento
Journal:  HPB (Oxford)       Date:  2011-08-19       Impact factor: 3.647

4.  Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Authors:  Hua-Xiang Xu; Tao Chen; Wen-Quan Wang; Chun-Tao Wu; Chen Liu; Jiang Long; Jin Xu; Ying-Jian Zhang; Run-Hao Chen; Liang Liu; Xian-Jun Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-13       Impact factor: 9.236

5.  Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?

Authors:  Thomas Schnelldorfer; Adam L Ware; Michael G Sarr; Thomas C Smyrk; Lizhi Zhang; Rui Qin; Rachel E Gullerud; John H Donohue; David M Nagorney; Michael B Farnell
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

6.  Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years.

Authors:  Chenyue Zhang; Shu Dong; Lei Wang; Songlin Yu; Yuwei Zheng; Yanyan Geng; Xiaoheng Shen; Haifeng Ying; Yuanbiao Guo; Jinming Yu; Qinglong Deng; Zhiqiang Meng; Zhaoshen Li; Hao Chen; Yehua Shen; Qiwen Chen
Journal:  Discov Med       Date:  2018-03       Impact factor: 2.970

7.  Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma.

Authors:  Georgios Gemenetzis; Vincent P Groot; Alex B Blair; Ding Ding; Sameer S Thakker; Elliot K Fishman; John L Cameron; Martin A Makary; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Surg Oncol       Date:  2018-10-31       Impact factor: 3.454

8.  Pancreatic cancer: challenges and opportunities.

Authors:  Huiyun Zhu; Tuo Li; Yiqi Du; Min Li
Journal:  BMC Med       Date:  2018-11-22       Impact factor: 8.775

9.  The role of single-incision laparoscopic peritoneal exploration in the management of patients with peritoneal metastases.

Authors:  Haythem Najah; Brice Malgras; Anthony Dohan; Caroline Gronnier; Clarisse Eveno; Marc Pocard
Journal:  Surg Endosc       Date:  2019-07-18       Impact factor: 4.584

10.  Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Qingcai Meng; Si Shi; Chen Liang; Jinfeng Xiang; Dingkong Liang; Bo Zhang; Yi Qin; Shunrong Ji; Wenyan Xu; Jin Xu; Quanxing Ni; Xianjun Yu
Journal:  J Cancer       Date:  2017-10-09       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.